Bezafibrate derivatives as potent effectors of hemoglobin.
Poyart
C
C
INSERM, Hôpital de Bicêtre, Le Kremlin.
Marden
M C
MC
Kister
J
J
D019794:2,3-Diphosphoglycerate; D000494:Allosteric Regulation; D000495:Allosteric Site; D001629:Bezafibrate / Q000031:analogs & derivatives / Q000493:pharmacokinetics / Q000494:pharmacology*; D002712:Chlorides / Q000494:pharmacology; D018360:Crystallography, X-Ray; D004163:Diphosphoglyceric Acids / Q000378:metabolism / Q000494:pharmacology; D004357:Drug Synergism; D004910:Erythrocyte Membrane / Q000378:metabolism; D004912:Erythrocytes / Q000187:drug effects; D006454:Hemoglobins / Q000737:chemistry / Q000187:drug effects*; D006801:Humans; D010100:Oxygen / Q000378:metabolism; D010108:Oxyhemoglobins / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism; D011485:Protein Binding; D011487:Protein Conformation; D012709:Serum Albumin; D013329:Structure-Activity Relationship
D002712:Chlorides; D004163:Diphosphoglyceric Acids; D006454:Hemoglobins; D010108:Oxyhemoglobins; D012709:Serum Albumin; D019794:2,3-Diphosphoglycerate; D010100:Oxygen; D001629:Bezafibrate